We evaluated the combination of locally delivered anti-mesothelin immunotoxins and systemic anti-CTLA-4 in both the 66C14-M murine breast cancer model and the AE17-M murine mesothelioma model. The gene discussed is CTLA4; the disease is breast cancer.